Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec.

Trial Profile

Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs Influenza A virus H1N1 vaccines (Primary) ; AS03A
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top